Monoclonal antibodies in non-small-cell lung cancer: Light at the end of the tunnel

F. Naddafi
{"title":"Monoclonal antibodies in non-small-cell lung cancer: Light at the end of the tunnel","authors":"F. Naddafi","doi":"10.15761/TIM.1000190","DOIUrl":null,"url":null,"abstract":"Lung cancer is the leading cause of death and non-small cell lung cancer (NSCLC) is considered as the most common type of lung cancer. Several conventional therapies, such as surgery, radiation, and chemotherapy are used for the treatment of lung cancer. But, these therapies could have multiple undesirable side effects. Therefore, there is an urgent need for therapeutic agents to improve the clinical outcomes for cases with NSCLC. Recently, therapeutic antibodies have shown promise for NSCLC treatment. The aim of this review is to discuss FDA-approved antibodies such as durvalumab, pembrolizumab, necitumumab and nivolumab in the treatment of NSCLC as well as Onartuzumab, a monoclonal antibody against c-MET, that was discontinued due to its lack of clinical activity. Furthermore, the aim of this manuscript is to give a brief overview about NSCLC therapeutic mAbs. *Correspondence to: Fatemeh Naddafi, Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tel: 982188209627; Fax: 982188209627; E-mail: fatemeh.naddafi@yahoo.com, fatemeh.naddafi@sbmu.ac.ir","PeriodicalId":23337,"journal":{"name":"Trends in Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Trends in Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/TIM.1000190","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Lung cancer is the leading cause of death and non-small cell lung cancer (NSCLC) is considered as the most common type of lung cancer. Several conventional therapies, such as surgery, radiation, and chemotherapy are used for the treatment of lung cancer. But, these therapies could have multiple undesirable side effects. Therefore, there is an urgent need for therapeutic agents to improve the clinical outcomes for cases with NSCLC. Recently, therapeutic antibodies have shown promise for NSCLC treatment. The aim of this review is to discuss FDA-approved antibodies such as durvalumab, pembrolizumab, necitumumab and nivolumab in the treatment of NSCLC as well as Onartuzumab, a monoclonal antibody against c-MET, that was discontinued due to its lack of clinical activity. Furthermore, the aim of this manuscript is to give a brief overview about NSCLC therapeutic mAbs. *Correspondence to: Fatemeh Naddafi, Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Tel: 982188209627; Fax: 982188209627; E-mail: fatemeh.naddafi@yahoo.com, fatemeh.naddafi@sbmu.ac.ir
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
非小细胞肺癌的单克隆抗体:隧道尽头的光
肺癌是导致死亡的主要原因,非小细胞肺癌(NSCLC)被认为是最常见的肺癌类型。几种传统疗法,如手术、放疗和化疗用于治疗肺癌。但是,这些疗法可能有多种不良副作用。因此,迫切需要治疗药物来改善非小细胞肺癌的临床预后。最近,治疗性抗体显示出治疗非小细胞肺癌的希望。本综述的目的是讨论fda批准的用于治疗NSCLC的抗体,如durvalumab, pembrolizumab, necitumumab和nivolumab,以及Onartuzumab,一种针对c-MET的单克隆抗体,由于缺乏临床活性而被停产。此外,本文的目的是对NSCLC治疗性单克隆抗体进行简要概述。*通讯:Fatemeh nadhafi,伊朗德黑兰Shahid Beheshti医科大学药物科学研究中心,电话:982188209627;传真:982188209627;电子邮件:fatemeh.naddafi@yahoo.com, fatemeh.naddafi@sbmu.ac.ir
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
PVAT mediated immunomodulation in vasculo-adipose balance in atherosclerosis Complex treatment after pathohistological and immunohistochemical analysis in synchronous neoplasms - anorectal achromatic malignant melanoma and gastric extrapleural solitary fibrous tumor Manifesto for research on intradermal vaccines proposed by the Italian Society of Mesotherapy Does complementary and alternative therapy work for SARS-CoV-2 (COVID-19)? Heart rate variability and heart rate under general anesthesia in rats of both sexes
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1